MESENCHYMAL-LIKE STEM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS, METHODS AND USES THEREOF

摘要

The disclosure provided herein relates generally to mesenchymal-like stem cells “hES-T-MiSC” or “T-MSC” and the method of producing the stem cells. The method comprises culturing embryonic stem cells under conditions that the embryonic stem cells develop through an intermediate differentiation of trophoblasts, and culturing the differentiated trophoblasts to hES-T-MSC or T-MSC, T-MSC derived cells and cell lineages “T-MSC-DL” are also described. Disclosed also herein are solutions and pharmaceutical compositions comprising the T-MSC and/or T-MSC-DL, methods of making the T-MSC and T-MSC-DL, and methods of using the T-MSC and T-MSC-DL for treatment and prevention of diseases, specifically, T-MSC and T-MSC-DL are used as immunosuppressive agents to treat multiple sclerosis and autoimmune diseases.

主权项

1. A method of producing trophoblast-derived mesenchymal stem cells (T-MSCs) from human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs), the method comprising:
(a) culturing hESCs or iPSCs in a medium comprising a bone morphogenetic protein (BMP) for a suitable first time period of 1 to 5 days sufficient for the hESC or iPSC to differentiate into trophoblasts, or together with a TGFb inhibitor to increase the differentiation efficiency; (b) dissociating trophoblast cells into single cells; (c) re-plating the trophoblast cells onto gelatin, vitronectin, laminin, fibronectin, Matrigel or collagen-coated plates; and (d) culturing the trophoblast cells for a suitable second time period of 4 to 10 days in a mesenchymal stem cell (MSC) growth medium containing LIF, bFGF or PDGF to increase expansion efficiency